Amphenol has reported its Q2 results — the print the last note was previewing — and the stock has sold off sharply, falling 9% on the week to $143.85, leaving a wide and now very visible gap between where the stock trades and where the Street thinks it should.
The analyst community had been notably bullish heading into the print. Multiple firms raised targets in mid-July, with Citigroup lifting to $195, Barclays to $200, and BofA lifting to $185 — all reiterating positive ratings ahead of earnings. The consensus mean target now sits at $190.82, implying roughly 33% upside from current levels. That gap is striking. Either the Street is right and the post-earnings selloff represents an overreaction, or targets will come down in the days ahead as analysts digest the numbers. The bull case rests on AI infrastructure spend (projected ~200% growth) and EV adoption driving connector demand. Bears counter with weakness in industrial production, automotive supply constraints, and the difficulty of sustaining acquisition-driven growth at current multiples. The PE multiple has compressed to 26.4x — down more than 5 points over the past month — and EV/EBITDA has pulled back to 15.4x, so some valuation relief has arrived, though the stock still prices in substantial execution.
Options positioning shifted noticeably after the event. The put/call ratio moved up to 0.79 following the print — still marginally below its 20-day average of 0.82, but the clear call-skew that defined the pre-earnings setup has evaporated. The z-score has flipped negative at -0.39, meaning options are now roughly in line with recent norms rather than leaning bullish. That's a clean reversal from the pre-earnings tilt described in the last note. The lending market remains a non-story: availability is effectively unlimited, borrowing costs have actually fallen by half on the week to just 0.19%, and short interest at 1.3% of float carries no meaningful squeeze pressure. The ORTEX short score of 29.3 — in the 79th percentile for short score rank — confirms there is no structural short-side conviction against the name.
Institutional ownership offers an important counterpoint to the price action. BlackRock holds 8.3% of shares and added modestly at the last report. Capital Research and Management added aggressively — 24 million shares in the most recent filing — bringing their stake to 5.3%. JP Morgan Asset Management added over 10 million shares. These are long-duration holders, and their recent accumulation predates the Q2 print. The insider picture is less encouraging: CEO Richard Norwitt sold over $18.7 million of stock across three transactions in early May, at prices around $142-$144 — essentially the current level. The CFO sold $15 million in February. Net insider selling over the past 90 days runs to roughly $132 million. These were likely planned disposals, but the timing means insiders were exiting at prices close to where the stock now sits after a major decline.
The one prior earnings reaction on record showed APH gained 2.5% on the day of the April 2026 print, then gave back those gains and more, finishing the following five days down 3.7%. That pattern — initial relief, subsequent fade — is worth keeping in mind as the market works through the Q2 numbers. The next earnings event is scheduled for late October.
What to watch now is whether analyst firms revise their targets materially lower in response to the print, or hold the line — the distance between the $190 consensus and $144 reality will be the dominant frame for how the stock trades into year-end.
See the live data behind this article on ORTEX.
Open APH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
